$CCCC

JPMorgan initiated coverage on C4 Therapeutics (NASDAQ:CCCC) with an Overweight rating and a $10.00 price target, citing the potential of cemsidomide in multiple myeloma. The firm projects U.S. peak sales of $500M-$600M by 2035 for cemsidomide and $3B-$4B by 2041 for its combination with elranatamab. The stock is currently trading at $2.85.

C4 Therapeutics (CCCC) presented Phase 1 trial data showing immune activation in multiple myeloma patients treated with cemsidomide. The study, involving 62 patients, demonstrated T-cell and natural killer cell activation at higher doses. The Phase 1b trial with elranatamab showed reduced T-cell exhaustion markers. CCCC's stock is currently at $2.94, down 2.48%.

C4 Therapeutics, Inc. (CCCC) filed an SEC Form 8-K — Regulation FD Disclosure. C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting Immunomodulatory Effects of Cem

C4 Therapeutics shares rose 3.8% in morning trading after the company reported Q2 2026 results. Net loss per share was $0.18, better than the $0.21 consensus, but revenue was $6.64M versus $8.2M expected, citing research wind-downs under Merck and Merck KGaA collaborations. Management said cemsidomide Phase 2 MOMENTUM and Phase 1b combo studies remain on track for 2027 data.

C4 Therapeutics, Inc. (CCCC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Cemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027 Phase 1 Data Present

C4 Therapeutics, Inc. (CCCC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cccc-20260624 0001662579 false 0001662579 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________ FORM 8-K _________________________________________________________________ CUR

C4 Therapeutics (NASDAQ:CCCC) surpassed analyst revenue expectations but reported a statutory loss smaller than predicted. Despite analysts cutting 2026 revenue forecasts, they also reduced estimated losses, leading to a 17% increase in the consensus price target to US$11.57. However, the wide range in analyst estimates suggests difficulty in accurately valuing the company, especially given projected revenue declines greater than the broader industry.

C4 Therapeutics has initiated a Phase 1b clinical trial combining cemsidomide with elranatamab and dexamethasone for relapsed or refractory multiple myeloma, targeting readout by mid-2027. The trial aims to assess optimal dosing and safety, with secondary measures including overall response and duration of response. This strategic move positions cemsidomide for combination therapies to achieve deeper and more durable responses in myeloma treatment.

C4 Therapeutics, Inc. has announced its financial results for the fourth quarter and full year 2025. The company also provided an update on recent business developments. Stakeholders are encouraged to consult the official press release for a detailed review of the figures and insights.

C4 Therapeutics reported its Q4 and full-year 2025 financial results, showing revenues of $35.9 million and a net loss of $105.0 million. The company ended 2025 with $297.1 million in cash, which is expected to fund operations until the end of 2028. Key clinical updates include the advancement of cemsidomide into a Phase 2 trial for multiple myeloma and a planned Phase 1b combination study.